Key Highlights

  • Shares fell 12.43% to USD 4.51 in pre-market trading on November 4, 2026.
  • The implied Tuesday close was about USD 5.15 (calculated), which puts the drop at USD 0.6402.
  • A 1-for-10 reverse split came into effect on June 11, 2026.
  • A public offering announced on March 6, 2026 brought in about USD 3.5 million gross, through 7.0 million shares and pre-funded warrants (calculated total).
  • A private Placement announced on November 3, 2025 raised USD 2.5 million at an effective USD 4.00 per share.

What Moved Shuttle Pharmaceuticals Before the Open (down USD 0.6402, 12.43%)

Shuttle Pharmaceuticals (NASDAQ:SHPH) traded 12.43% lower at USD 4.51 in pre-market trading on November 4, 2026, against the Tuesday, November 3, 2026 close. The screen figures imply a prior close of about USD 5.15 (calculated), so the stock is handing back part of its recent strength.

No company press release, Earnings report or regulatory filing dated November 2, 3 or 4, 2026 was identified. The move therefore appears to reflect trading in a small share base with a thin order book. That is an inference rather than a confirmed cause.

The Capital Raises Behind the Share Count

In a company press release dated March 6, 2026, Shuttle reported selling 2,238,800 shares and pre-funded warrants for 4,761,200 shares in a public offering. Gross proceeds were about USD 3.5 million, which implies roughly USD 0.50 per share before the later reverse split (calculated). Up to USD 1.5 million of net proceeds was earmarked for marketing, with the remainder directed to Working Capital and general corporate purposes.

After adjusting for the 1-for-10 reverse split, that price works out to roughly USD 5.00 per share (calculated), close to where the stock trades now. Earlier, on November 3, 2025, the company announced a USD 2.5 million private placement at an effective USD 4.00 per share.

Business Background and Recent Updates

Shuttle Pharmaceuticals Holdings is based in Gaithersburg, Maryland, and develops cancer therapy candidates designed to improve outcomes from radiation treatment. On November 21, 2025, it announced the Acquisition of an AI health platform, broadening its focus beyond conventional drug development.

Stockholders approved board discretion over a reverse split ranging from 1-for-2 to 1-for-150 at the annual meeting on May 21, 2026. The board selected 1-for-10 on June 1, 2026. A regulatory filing showed that split-adjusted trading began on June 11, 2026, with warrants and convertible preferred stock adjusted proportionally. That filing was signed by an interim co-chief executive officer.

Balance Sheet and Risks

Detailed cash and Debt figures for the most recent quarter were not confirmed in the material reviewed, so none are cited here. The pattern of repeated small Equity raises, pre-funded warrants and a reverse split points to continuing funding needs and a risk of further dilution.

Trading below USD 5 per share makes this a penny stock, and shares in this category can be volatile, thinly traded and prone to sharp reversals. Warrant exercises and new offerings could add to the share count and weigh on the price.

What to Watch Next

Investors will look for the Quarterly Report covering the period ended September 30, 2026, which should update cash, spending and progress on the AI health platform. Any new offering, warrant inducement or Nasdaq correspondence would also matter.

Management commentary on strategy and leadership, including the interim co-chief executive structure, is another item to follow. Trading Volume once regular hours open on November 4, 2026 will show whether the pre-market decline holds.